
HighField Biopharmaceuticals 提交两种具有不同抗癌活性的 ADCplex™ 免疫脂质体 IND 申请,以克服当前 ADC 的局限性
HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs The new technology behind HighField’s immu ...